...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Overcoming the stability, solubility and extraction challenges in reversed-phase UHPLC–MS/MS bioanalysis of a phosphate drug and its prodrug in blood lysate
【24h】

Overcoming the stability, solubility and extraction challenges in reversed-phase UHPLC–MS/MS bioanalysis of a phosphate drug and its prodrug in blood lysate

机译:克服血液裂解物中磷脂和其前药的反相UHPLC-MS / MS生物分析中的稳定性,溶解度和提取挑战

获取原文
获取原文并翻译 | 示例
           

摘要

BMS-986104 is a S1P1R modulator drug candidate under development and has been evaluated in Phase I clinical trials. BMS-986104 functions as a prodrug and undergoes enzymatic transformationsin vivoto form the pharmacologically active phosphate drug, BMS-986104-P. Here, we report approaches to overcome the stability, solubility and extraction challenges in developing a sensitive, accurate and rugged LC–MS/MS method for the simultaneous quantification of the phosphate drug and its prodrug in blood lysate. An effective stabilization strategy using a cocktail of phosphatase and kinase inhibitors was developed to ensure the stability of both analytes during sample collection, storage, and processing. A combination of surfactant (CHAPS) and weak base (Tris) was found to be able to effectively improve the solubilization of the phosphate drug. The blood lysate samples were extracted by protein precipitation followed by solid-phase extraction using an Oasis HLB 96-well SPE plate. The method achieved acceptable matrix effect and recovery for the two analytes that have very different chemical properties. Stable-isotope labeled D6-BMS-986104 and D13-BMS-986104-P were utilized as the internal standards. Chromatographic separation was achieved using isocratic conditions on an Acquity UPLC BEH C18 analytical column. The two analytes and their internal standards were detected by positive ion electrospray tandem mass spectrometry. The calibration curves, which ranged from 2.00 to 2000?ng/mL for BMS-986104 and 4.00 to 4000?ng/mL for BMS-986104-P, were fitted to a 1/x2 weighted linear regression model. The intra-assay precision was within ±5.0% CV, inter-assay precision was within ±4.9% CV, and the assay accuracy was within ±5.8% of the nominal values for both analytes in rat blood lysate. The method was validated and successfully applied to support multiple pre-clinical toxicity studies.
机译:BMS-986104是S1P1R调节剂药物候选药物的开发,并已在I期临床试验中进行评估。 BMS-986104用作前药并经过酶转化,形成药理学活性磷酸盐,BMS-986104-P。在此,我们报告了克服稳定性,溶解度和提取挑战的方法,以在血液裂解物中同时定量磷酸盐药物及其前药的敏感,准确和坚固的LC-MS / MS方法。开发了使用磷酸酶和激酶抑制剂的混合物的有效稳定策略,以确保在样品收集,储存和加工过程中的两种分析物的稳定性。发现表面活性剂(CHAPS)和弱碱(TRIS)的组合能够有效地改善磷脂的溶解。通过蛋白质沉淀提取血液裂解物样品,然后使用Oasis HLB 96孔Spe板进行固相萃取。该方法达到了具有截然不同的化学性质的两种分析物的可接受的基质效应和恢复。稳定同位素标记为D6-BMS-986104和D13-BMS-986104-P作为内部标准。在Acquity UPLC BEH C18分析柱上的等离子条件实现色谱分离。通过正离子电喷雾串联质谱法检测两种分析物及其内标。对于BMS-986104和400至4000℃的校准曲线,为BMS-986104和400至4000°F用于BMS-986104-P,适用于1 / X2加权线性回归模型。测定内精度在±5.0%CV范围内,测定间精度在±4.9%CV范围内,测定精度在大鼠血液裂解物中的分析物中的标称值的±5.8%内。该方法经过验证并成功地应用于支持多个临床前毒性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号